USPTO serial 79345490
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jill Anderfuren
Jill Anderfuren Lewis Brisbois Bisgaard & Smith LLP550 West Adams StreetSuite 300Chicago, IL 60661| Class | Description | Status | First use |
|---|---|---|---|
| 001 | biological and chemical products for manufacturing and research use in the pharmaceutical industry; chemical reagents for the manufacture of therapeutic immunotherapy solutions | ACTIVE | — |
| 005 | pharmaceutical products for use in oncology and immunotherapy; biological and pharmaceutical preparations for the treatment of cancer and tumors; biological and pharmaceutical preparations for cancer and tumor treatment using immunotherapy; therapeutic preparations being solutions, namely, antigen, antibodies, T-cells in the nature of preparations for treatment of cancer and tumors; biological materials, preparations, reagents being pharmaceutical products for medical use for the treatment of cancer and tumors; diagnostic preparations for medical purposes, namely, antigens, antibodies, cells for therapeutic use | ACTIVE | — |
| 040 | Custom manufacture of pharmaceutical products for therapeutic use in immunotherapy; custom manufacture of therapeutic solutions, namely, antigens, antibodies, T cells | ACTIVE | — |
| 042 | Scientific research services for medical purposes; scientific research and product development, namely, antigen identification, screening and development services; scientific and technological research services in the field of oncology and immunotherapy; scientific laboratory services; providing scientific and medical research information with regard to immunotherapy; scientific research and development, namely, providing services for identifying, analyzing, authenticating, purifying and developing biological material from a genomic platform; scientific research, namely, epigenetic antigen screening and identification services for therapeutic research purposes; medical research, namely, genomic and epigenetic characterization services for identifying drug candidates in immunotherapy; providing medical and scientific research information, namely, designing algorithms and models for use in scientific and medical research; Providing temporary use of online non-downloadable computer software platforms featuring algorithms for analyzing cells, antigens, tissues, gene expressions, gene sequences, genome annotations, antigen characteristics and immunological responses; Providing temporary use of an online non-downloadable computer software platform for use in forecasting the characteristics of antigens and immunological responses through the use of algorithms | ACTIVE | — |
| 044 | providing medical information with regard to immunotherapy | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 18, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 22, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 22, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 21, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 21, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 21, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 5, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 5, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 4, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 16, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 16, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 16, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 2, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 2, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 2, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 7, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 7, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 7, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 7, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 6, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 2, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jan 9, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 8, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 26, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 25, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 21, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 26, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 22, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 21, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |